| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, ... The Lancet 389 (10064), 56-66, 2017 | 3482 | 2017 |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2075 | 2017 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 780 | 2021 |
| Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma JC Wu, YH Huang, GY Chau, CW Su, CR Lai, PC Lee, TI Huo, IJ Sheen, ... Journal of hepatology 51 (5), 890-897, 2009 | 483 | 2009 |
| Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B YH Huang, LT Hsiao, YC Hong, TJ Chiou, YB Yu, JP Gau, CY Liu, ... J Clin Oncol 31 (22), 2765-2772, 2013 | 365 | 2013 |
| A versatile thermally activated delayed fluorescence emitter for both highly efficient doped and non-doped organic light emitting devices WL Tsai, MH Huang, WK Lee, YJ Hsu, KC Pan, YH Huang, HC Ting, ... Chemical communications 51 (71), 13662-13665, 2015 | 346 | 2015 |
| Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial RS Finn, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, O Yokosuka, ... Journal of hepatology 69 (2), 353-358, 2018 | 344 | 2018 |
| Gastrointestinal and liver manifestations in patients with COVID-19 IC Lee, TI Huo, YH Huang Journal of the Chinese Medical Association 83 (6), 521-523, 2020 | 308 | 2020 |
| Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients CW Su, YH Huang, TI Huo, HH Shih, IJ Sheen, SW Chen, PC Lee, ... Gastroenterology 130 (6), 1625-1635, 2006 | 280 | 2006 |
| Prognosis of hepatocellular carcinoma: assessment of eleven staging systems PH Liu, CY Hsu, CY Hsia, YH Lee, CW Su, YH Huang, FY Lee, HC Lin, ... Journal of hepatology 64 (3), 601-608, 2016 | 273 | 2016 |
| Genetic polymorphisms of manganese superoxide dismutase, NAD (P) H: quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury YS Huang, WJ Su, YH Huang, CY Chen, FY Chang, HC Lin, SD Lee Journal of hepatology 47 (1), 128-134, 2007 | 260 | 2007 |
| A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements M Kudo, KH Han, SL Ye, J Zhou, YH Huang, SM Lin, CK Wang, M Ikeda, ... Liver cancer 9 (3), 245-260, 2020 | 213 | 2020 |
| Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system CY Hsu, YH Lee, CY Hsia, YH Huang, CW Su, HC Lin, RC Lee, YY Chiou, ... Hepatology 57 (1), 112-119, 2013 | 205 | 2013 |
| A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System CY Hsu, YH Huang, CY Hsia, CW Su, HC Lin, CC Loong, YY Chiou, ... Journal of hepatology 53 (1), 108-117, 2010 | 191 | 2010 |
| Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study CF Tsai, MH Chen, YP Wang, CJ Chu, YH Huang, HC Lin, MC Hou, ... Gastroenterology 152 (1), 134-141, 2017 | 189 | 2017 |
| Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma≤ 2 cm in a propensity score model PH Liu, CY Hsu, CY Hsia, YH Lee, YH Huang, YY Chiou, HC Lin, TI Huo Annals of surgery 263 (3), 538-545, 2016 | 186 | 2016 |
| Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas HH Hung, YY Chiou, CY Hsia, CW Su, YH Chou, JH Chiang, WY Kao, ... Clinical Gastroenterology and Hepatology 9 (1), 79-86, 2011 | 173 | 2011 |
| Incorporation of a CN group into mCP: a new bipolar host material for highly efficient blue and white electrophosphorescent devices Ming-Shiang Lin, Shang-Jung Yang, Hong-Wei Chang, Yi-Hsiang Huang, Yu-Tang ... Journal of Materials Chemistry, 16114-16120, 2012 | 171 | 2012 |
| RESORCE Investigators Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled … J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, ... Lancet 389 (10064), 56-66, 2017 | 168 | 2017 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative … LT Chen, E Martinelli, AL Cheng, G Pentheroudakis, S Qin, ... Annals of Oncology 31 (3), 334-351, 2020 | 156 | 2020 |
Chung-Chih WuProfessor, National Taiwan University在 ntu.edu.tw 的電子郵件地址已通過驗證
